top of page

Inflection Biosciences Selected to Present at International Investor Forum

Dublin, Ireland, November 21, 2012

Inflection Biosciences limited was selected as one of 25 Irish companies to present at the 5th Enterprise Ireland International Investor forum, taking place in London today, Wednesday 21 November 2012. Darren Cunningham Chief Executive officer of Inflection Biosciences will present at the event, providing an overview of the company’s strategy, in-licensing activities and financing plans for 2013.

About the Enterprise Ireland International Investor Forum Over 114 venture capital, Corporate and other investors from North America, Britain, Mainland Europe and Asia are attending the Enterprise Ireland International Investor Forum in London today (Wednesday 21 November 2012), to meet 25 Irish companies from a variety of sectors including Financial Services, Cleantech, Software and Lifesciences. The forum is aimed at getting new investment to fund the significant growth plans of these companies. The new investment is being sought on the basis of syndicated investment between Irish and International VCs. This is the fifth year the event is taking place, where the 25 Irish companies will make presentations to the international investors and leading Irish VC firms, as well as taking part in over 150 formal meetings.

This increased interest augurs well for the syndicated investments between Irish and International VCs. In the last five years, over 50 international VCs have invested in Irish companies and syndicated with Irish Venture Capital firms.

About Inflection Biosciences Limited Inflection Biosciences is an early stage, drug development company with a focus on developing innovative small molecule therapeutics that address unmet needs for cancer. Inflection Biosciences is dedicated to identifying excellent early stage cancer research from academic institutes and other companies around the world. The company will use its expertise to progress the most promising programs through pre-clinical and early clinical stages, partnering for later stage clinical development and commercialisation. For more information please visit

Contact: Darren Cunningham, Chief Executive Officer Tel: +353 (0)1 4003615 Email:


bottom of page